Previous 10 | Next 10 |
2024-03-28 05:42:57 ET Akebia Therapeutics ( NASDAQ: AKBA ) shares surged over 25% premarket on Thursday after the U.S. Food and Drug Administration (FDA) approved its Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adult patients o...
2024-03-28 05:41:26 ET More on related stocks RH (RH) Q4 2023 Earnings Call Transcript RH: Q4 Earnings, Improved Results May Be Coming, But Are Likely Priced In MillerKnoll, Inc. (MLKN) Q3 2024 Earnings Call Transcript Intuitive Machines files to sell $300M c...
2024-03-22 15:00:00 ET More on the markets Wall Street Lunch: Fed Not Spooked By Recent Inflation SPY: Don't Fall For The Greed SPY: Assessing Economic Risks And Market Trends (Technical Analysis, Rating Downgrade) Investors sell $66B worth of money market fu...
2024-03-14 17:17:53 ET More on Akebia Akebia Therapeutics closes up to $55M loan facility Seeking Alpha’s Quant Rating on Akebia Historical earnings data for Akebia Financial information for Akebia Read the full article on Seeking Alpha ...
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights PR Newswire Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing a...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to b...
2024-01-30 08:30:12 ET More on Akebia Akebia Therapeutics, Inc. (AKBA) Q3 2023 Earnings Call Transcript Akebia Therapeutics: Waiting For Round 2 Akebia Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Akebia Historical earnings data for...
Akebia Secures $55 Million Term Loan Financing PR Newswire Strengthens Balance Sheet Ahead of Potential Vadadustat Approval on March 27, 2024 CAMBRIDGE, Mass. , Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasda...
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer PR Newswire CAMBRIDGE, Mass. , Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose ...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference PR Newswire CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to b...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...